Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Zenas BioPharma, Inc. (“Zenas BioPharma” or the “Company”) (NASDAQ: ZBIO) securities in connection with the initial public offering (the “IPO”) held on or around September 13, 2024 (the “Class Period”) and/or which said securities are traceable thereto. The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.

The Complaint alleges that the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (i) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (ii) as a result, Defendants’ public statements were materially false and misleading at all relevant times and negligently prepared. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.



.